Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

142.88USD
21 Sep 2018
Change (% chg)

$0.90 (+0.63%)
Prev Close
$141.98
Open
$142.25
Day's High
$143.13
Day's Low
$141.70
Volume
7,735,621
Avg. Vol
1,922,704
52-wk High
$148.32
52-wk Low
$118.62

Select another date:

Fri, Sep 7 2018

Photo

J&J to work with India on compensation for recalled hip implants

MUMBAI Johnson & Johnson (J&J) said it would work with the Indian government to compensate patients who had suffered from hip implants that were recalled by the U.S. healthcare firm eight years ago after data showed high failure rates.

J&J to work with India on compensation for recalled hip implants

MUMBAI Johnson & Johnson (J&J) said it would work with the Indian government to compensate patients who had suffered from hip implants that were recalled by the U.S. healthcare firm eight years ago after data showed high failure rates.

Bayer, J&J's bid to further widen use of Xarelto hits snag

FRANKFURT Bayer and Johnson & Johnson's campaign to widen the patient group for their heart drug Xarelto hit a snag when two smaller studies failed to show a statistically reliant benefit.

Bayer, J&J's bid to further widen use of Xarelto hits snag

FRANKFURT, Aug 27 Bayer and Johnson & Johnson's campaign to widen the patient group for their heart drug Xarelto hit a snag when two smaller studies failed to show a statistically reliant benefit.

Bayer, J&J's heart drug Xarelto fails trial to widen use

FRANKFURT Bayer and Johnson & Johnson's campaign to widen the market for its heart drug Xarelto hit a snag on Sunday when a study for a potential new patient subgroup failed to show a statistically reliant benefit.

Bayer, J&J's heart drug Xarelto fails trial to widen use

FRANKFURT, Aug 26 Bayer and Johnson & Johnson's campaign to widen the market for its heart drug Xarelto hit a snag on Sunday when a study for a potential new patient subgroup failed to show a statistically reliant benefit.

Missouri judge affirms $4.69 billion talc verdict, J&J vows to appeal

A Missouri trial court judge has affirmed the massive $4.69 billion verdict against Johnson & Johnson in a case involving 22 women and their families who alleged the company's talc-based products, including its baby powder, contain asbestos and caused them to develop ovarian cancer.

Missouri judge affirms $4.69 billion talc verdict, J&J vows to appeal

A Missouri trial court judge has affirmed the massive $4.69 billion (3.63 billion pounds) verdict against Johnson & Johnson in a case involving 22 women and their families who alleged the company's talc-based products, including its baby powder, contain asbestos and caused them to develop ovarian cancer.

Missouri judge affirms $4.69 bln talc verdict, J&J vows to appeal

Aug 22 A Missouri trial court judge has affirmed the massive $4.69 billion verdict against Johnson & Johnson in a case involving 22 women and their families who alleged the company's talc-based products, including its baby powder, contain asbestos and caused them to develop ovarian cancer.

U.S. insurers grilled on exposure to $4.7 billion J&J talc verdict

Wall Street is trying to figure out whether the U.S. insurance industry will bear any costs from a record $4.69 billion judgment against Johnson & Johnson awarded to customers and their families who claimed that asbestos-contaminated talc caused ovarian cancer.

Select another date: